How research helped lead to FDA approval of a pediatric neuroblastoma drug

In 2003, the first year of her fellowship in pediatric oncology, two of Giselle Saulnier Sholler’s first three patients had died from neuroblastoma, closely matching the 30% survival rate expected at the time for high-risk neuroblastoma. She knew research was the only way to change these outcomes.

Leave A Comment

Your email address will not be published. Required fields are marked *